No Data
Zhejiang Conba Pharmaceutical (600572.SH): Participating in the tenth batch of national pharmaceutical centralized procurement intends to bid.
On December 13, Gelonghui reported that Zhejiang Conba Pharmaceutical (600572.SH) announced that on December 12, 2024, the company and its wholly-owned subsidiary Zhejiang Jinhua Conba Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinhua Conba") participated in the bidding of the tenth national centralized procurement organized by the National Joint Procurement Office (hereinafter referred to as the "Joint Procurement Office"). After the bidding and evaluation conducted by the Joint Procurement Office, the company's product Amikacin Sulfate Injection is expected to win the bid for this centralized procurement. The Amikacin Sulfate Injection has been selected for supply provinces based on market potential in each province.
CONBA Pharma Gets Regulatory Nod to Make Changes to Amikacin Sulfate Injection
Zhejiang Conba Pharmaceutical (600572.SH): Amikacin Sulfate Injection pharmaceutical passed the generic drug consistency evaluation
Zhejiang Conba Pharmaceutical (600572.SH) announced on December 3 that the company has received the Drug Administration of China's approval for the issuance of the Approval Notice for the supplementary application of Amikacin Sulfate Injection (hereinafter referred to as "the pharmaceutical"), which has passed the evaluation of generic drug quality and efficacy consistency. Amikacin Sulfate is an aminoglycoside antibiotic, clinically applicable to severe infections caused by sensitive gram-negative rods such as Pseudomonas aeruginosa and other Pseudomonas species, Escherichia coli, and Staphylococcus species (methicillin-sensitive strains), such as septicemia or sepsis, bacterial endocarditis, etc.
Zhejiang CONBA PharmaceuticalLtd's (SHSE:600572) Earnings Have Declined Over Five Years, Contributing to Shareholders 16% Loss
Zhejiang CONBA Pharmaceutical Gets Approval for Hair Loss Cream in China
Zhejiang Conba Pharmaceutical (600572.SH): Minoxidil lotion obtained pharmaceutical registration certificate.
On November 27, Geelong reported that zhejiang conba pharmaceutical (600572.SH) announced that its wholly-owned subsidiary, Hangzhou Zhejiang Conba Pharmaceutical Co., Ltd., has received the "Drug Registration Certificate" for 5% and 2% minoxidil lotion issued by the National Medical Products Administration. The original research of minoxidil lotion is by the USA company Johnson & Johnson. The 2% lotion was approved for listing in the USA in 1988 for the treatment of hair loss in men and women; the 5% lotion was approved for listing in the USA in 1997, indicated for male hair loss.
Zhejiang CONBA Pharmaceutical Co.,Ltd.'s (SHSE:600572) Shares Lagging The Market But So Is The Business
